Senior Bioinformaticus with experience in tumor immunology
Our group has pioneered neoadjuvant immunotherapy in melanoma, and focuses on understanding pre-requisites for response upon neoadjuvant immunotherapy, better patient selection, and subsequent personalized combination therapies of targeted and immunotherapies.
Our group consists of basic researchers and physician researchers to ensure the direct translation of our laboratory findings into early phase clinical trials, and also back to bench. Your project will focus on gaining understanding on modulation of tumor immune infiltration, big data analysis of patient cohorts treated with neoadjuvant checkpoint inhibition, and high throughput screens identifying new modulators of immune activation.
Jouw ontwikkelingsmogelijkheden en arbeidsvoorwaarden
You will collaborate with scientists and clinicians with expertise in different disciplines, all focusing on cancer immunotherapies. You will have the opportunity to follow high-quality courses offered by the NKI postdoc career development program.
Your temporary employment will be initially for a period of two years. The gross salary per month will range from € 2.798,- to € 4.111,- according to the FWG-function group 55, and depends on previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals
Applications can be submitted through the link below, and should include your CV, a motivation letter, and the contact information of your references.
Rozeman EA, Menzies AM van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Torres Acosta A, ter Meulen S, Koenen AM, Bosch LJ, Shannon K, Pronk LM, Gonzalez M, Ch’ng S, Emanuelsson H, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, and Blank CU. Identification of a favourable combination scheme of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: a multicentre randomised phase 2 study (OpACIN-neo). Lancet Oncol. 2019 Jul;20(7):948-960
O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019 Apr 30